Arcellx (ACLX) Gains from Investment Securities (2021 - 2025)
Arcellx's quarterly Gains from Investment Securities came in at $546938.0 in Q3 2025, up 36.39% year-on-year from $401000.0 in Q3 2024, and down 47.66% quarter-over-quarter from $1.0 million in Q2 2025.
Arcellx has reported Gains from Investment Securities for 5 years, with the latest figure at $546938.0 in Q3 2025.
- For the quarter ending Q3 2025, Gains from Investment Securities rose 36.39% year-over-year to $546938.0; the trailing twelve-month figure through Dec 2025 stood at -$193000.0 (changed N/A YoY), and the FY2025 full-year result was $6.8 million, down 6.45% from the prior year.
- Gains from Investment Securities for Q3 2025 stood at $546938.0, down from $1.0 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $15.4 million in Q4 2023, with the low at -$9.3 million in Q4 2022.
- Average Gains from Investment Securities over 5 years is $1.2 million, with a median of $546938.0 recorded in 2025.
- Year-over-year, Gains from Investment Securities soared 2471.24% in 2023 and slumped 200.32% in 2024.
- Tracing ACLX's Gains from Investment Securities over 5 years: stood at -$333000.0 in 2021, then slumped by 2692.19% to -$9.3 million in 2022, then soared by 265.43% to $15.4 million in 2023, then plunged by 109.54% to -$1.5 million in 2024, then soared by 137.28% to $546938.0 in 2025.
- The last three Gains from Investment Securities figures came in at $546938.0 (Q3 2025), $1.0 million (Q2 2025), and $229000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 546,938.00 |
| Sep 30, 2025 | 546,938.00 |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | -1.47 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | 401,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.52 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Dec 31, 2023 | 15.38 Mn |
| Dec 31, 2023 | 15.38 Mn |
| Jun 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 6.50 Mn |
| Mar 31, 2023 | 745,660.00 |
| Mar 31, 2023 | 745,660.00 |
| Dec 31, 2022 | -9.30 Mn |
| Dec 31, 2022 | -9.30 Mn |
| Sep 30, 2022 | 3.45 Mn |
| Sep 30, 2022 | 3.45 Mn |
| Jun 30, 2022 | 845,067.00 |
| Jun 30, 2022 | 845,067.00 |
| Mar 31, 2022 | 29,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Sep 30, 2021 | -333,000.00 |
| Sep 30, 2021 | -333,000.00 |
| Jun 30, 2021 | 952,804.00 |
| Jun 30, 2021 | 952,804.00 |
| Mar 31, 2021 | 121,000.00 |
| Mar 31, 2021 | 121,000.00 |